At the news
? NEUTRALIMPACT 5/10 PRESS-RELEASE filed May 13, 2026 at 07:30 ET
Abeona reported Q1 2026 net product revenue of $8.7M from ZEVASKYN, up from $2.4M in Q4 2025, with three patients treated. Net loss widened to $(17.1)M ($(0.30)/share) from $(12.0)M a year ago, driven by SG&A ramp-up and a $7.0M licensing payment for ABO-701. Cash burn and lack of profitability keep the stock in speculative territory despite commercial progress.
- Q1 2026 net product revenue $8.7M (vs $2.4M Q4 2025, $0 in Q1 2025)
- Net loss $(17.1)M or $(0.30)/share vs $(12.0)M or $(0.24)/share in Q1 2025
- Cash, equivalents & short-term investments $168.3M as of March 31, 2026 (down from $191.4M Dec 31, 2025)
- Three patients treated with ZEVASKYN in Q1 2026; QTC network expanded to six sites
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access